Another entry to the tomosynthesis market; Family wins battle to have son undergo proton therapy for brain tumor;

News From Around the Web

> The U.S. Food and Drug Administration has approved GE's new SenoClaire 3-D Tomosynthesis device, adding another player to the tomosynthesis market, Investor's Business Daily reports. Hologic pioneered 3-D breast imaging and Siemens has announced it is developing its own tomosynthesis device. Article

> Two radiologists who used image-guided injection to inject fungus-tainted steroids into at least 30 patients are fighting liability claims, arguing that they are only liable if plaintiffs looked to bring medical malpractice claims against them, the National Law Journal reports. The case has to with the tainted steroid methylprednisolone acetate compounded by the New England Compounding Center. Article

> A British family has been given permission to fly to Prague in order to have their five-year boy, who is suffering from a brain tumor, receive proton therapy, according to The Telegraph. The ruling by a British High Court judge allowed the boy's parents to take him to Prague eight days after they had removed him from a hospital in Southampton England after a disagreement with that hospital's oncologists, and drove him to Spain. Article

Health IT News

> Only weeks away from the original ICD-10 deadline, just 11 percent of healthcare organizations said they are fully ready to implement the new coding system, according to a survey by SearchHealthIT and the College of Healthcare Information Management Executives. Article

Health Finance News

>The Centers for Medicare & Medicaid Services wants to end the long wrangling with hospitals over short-term inpatient stays. CMS offered to pay hospitals to settle the cases that are in dispute or under appeal, which may total as many as 800,000. The total sum represents 68 percent of what the hospitals say they are owed, according to a notice posted on the CMS website, and could run into the hundreds of millions of dollars. Article

And Finally... Beware of the spider-dog. Article